The Complix management team

Dr Mark Vaeck, Chief Executive Officer

Mark Vaeck has more than 30 years of experience in the biotech and pharma industry and has raised close to €100 million in equity financing for his companies. In 2008, he co-founded Complix and was appointed CEO in May 2010.

Prior to this, Mark was the founding CEO of ActoGeniX (Belgium) from 2006 until 2010. He was also the founding CEO of Ablynx (Belgium) from 2001 until 2006. Before joining Ablynx, Mark was COO of Ceres Inc (US), a NASDAQ listed company developing innovative technologies for biofuel production. From 1987 to 1998, he held several business development and general management positions in the biotech and pharma industry, including at UCB, Chiron, Keygene and PGS.

Mark holds a PhD in Immunology from the Free University of Brussels.

Dr Yvonne McGrath, Chief Scientific Officer

Yvonne McGrath has 18 years of biotech and pharma industry experience. Before joining Complix as CSO in May 2014, she was Head of Development at Immunocore, and before that Head of Preclinical Development and Chemistry and Manufacturing Controls (CMC). In these positions, she successfully developed and executed late preclinical and early clinical strategy for a novel platform technology and led manufacturing and CMC strategy for a new biological entity targeting cancer.

Yvonne holds a PhD from the University of Wales, College of Medicine.

Dr Ignace Lasters, Chief Technology Officer

Ignace Lasters has over 30 years of experience in the life science industry. He has published over 60 internationally peer-reviewed articles and is named inventor on numerous patent applications. In 2008, Ignace co-founded Complix and became its first CEO. From June 2010, Ignace assumed the role of CSO and, more recently, CTO at Complix.

Prior to this, Ignace acted as CEO/CSO of Algonomics from 1999-2008, until it was acquired by Lonza. Ignace co-founded Algonomics, a bioinformatics company dedicated to immunogenicity analysis and antibody engineering.

Ignace holds a PhD in Biochemistry from the Free University of Brussels.

Complix Cell Penetrating Alphabodies

A new revolutionary class of therapeutics targeting oncogenic intracellular targets